Clinical outcomes of HER2-positive metastatic breast cancer patients with brain metastasis treated with lapatinib and capecitabine: an open-label expanded access study in Korea

BACKGROUND: To evaluate efficacy in patients with brain metastasis (BM) on entry into the lapatinib expanded access program (LEAP). METHODS: LEAP is a worldwide, single-arm, open-label study. HER2-positive, locally-advanced or metastatic breast cancer patients with progression after an anthracycline...

Descripción completa

Detalles Bibliográficos
Autores principales: Ro, Jungsil, Park, Sohee, Kim, Sung- Bae, Kim, Tae You, Im, Young Hyuk, Rha, Sun Young, Chung, Joo Seop, Moon, Hanlim, Santillana, Sergio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2012
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3480888/
https://www.ncbi.nlm.nih.gov/pubmed/22839200
http://dx.doi.org/10.1186/1471-2407-12-322

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3480888/
https://www.ncbi.nlm.nih.gov/pubmed/22839200
http://dx.doi.org/10.1186/1471-2407-12-322

Ejemplares similares